CAR-T Cell Therapy

CAR-T cell therapy, short for chimeric antigen receptor T-cell therapy, is a form of adoptive cell transfer in which a patient's own immune cells are extracted, genetically modified, multiplied, and reinfused to attack cancer. The scientific foundation was laid by immunologist Zelig Eshhar at the Weizmann Institute in the late 1980s, who first fused an antibody's antigen-recognition domain to the T-cell receptor's signalling machinery. The therapy belongs to the broader field of immunotherapy and is classified as a gene therapy and an Advanced Therapy Medicinal Product. The first regulatory approval came in August 2017, when the United States Food and Drug Administration cleared Novartis's Kymriah (tisagenlecleucel) for refractory paediatric and young-adult B-cell acute lymphoblastic leukaemia, followed weeks later by Gilead/Kite's Yescarta (axicabtagene ciloleucel) for large B-cell lymphoma. In India, the therapy is regulated by the Central Drugs Standard Control Organisation under the Drugs and Cosmetics Act and the New Drugs and Clinical Trials Rules, 2019.

The procedure proceeds through a defined sequence. First, leukapheresis is performed: blood is drawn from the patient and circulated through a machine that separates and collects white blood cells, particularly T lymphocytes, returning the remaining components to the body. The harvested T cells are then transported to a manufacturing facility, where they are activated and genetically engineered—usually with a disabled lentivirus or retrovirus—to insert the gene encoding the chimeric antigen receptor. This synthetic receptor combines an extracellular antibody fragment that binds a tumour-specific surface protein (commonly CD19 in B-cell malignancies) with intracellular signalling and co-stimulatory domains. The modified cells are expanded in culture to hundreds of millions, undergo quality testing, and are cryopreserved. Before reinfusion, the patient receives lymphodepleting chemotherapy (typically fludarabine and cyclophosphamide) to create immunological space, after which the engineered cells are returned in a single infusion.

Several structural variants exist. First-generation CARs carried only the CD3-zeta signalling domain and showed poor persistence; second-generation constructs added one co-stimulatory domain (CD28 or 4-1BB) and form the basis of all currently approved products; third-generation designs incorporate two co-stimulatory domains. Beyond CD19, approved targets now include B-cell maturation antigen (BCMA) for multiple myeloma, addressed by products such as Abecma (idecabtagene vicleucel) and Carvykti (ciltacabtagene autoleucel). The dominant model is autologous—using the patient's own cells—but research into allogeneic or "off-the-shelf" CAR-T from healthy donors aims to reduce cost and manufacturing time, as does the development of CAR-NK (natural killer) cells and in-vivo engineering approaches that deliver the genetic instructions directly inside the body.

India achieved a landmark in October 2023 when the CDSCO granted market authorisation to NexCAR19 (actalycabtagene autoleucel), developed by ImmunoACT, a company incubated at the Indian Institute of Technology Bombay in collaboration with Tata Memorial Centre. Marketed as the country's first indigenous CAR-T therapy for relapsed or refractory B-cell lymphomas and leukaemia, it was priced at roughly ₹30–42 lakh—substantially below the US figure exceeding US$400,000. Prime Minister Narendra Modi formally launched it at IIT Delhi in April 2024, framing it as an instance of "Make in India" applied to advanced medicine. Globally, six CAR-T products had received FDA approval by 2024, and regulatory clearances followed from the European Medicines Agency and authorities in China, where domestic developers have advanced numerous candidates.

CAR-T therapy must be distinguished from adjacent modalities. Unlike checkpoint inhibitors such as pembrolizumab, which release pre-existing brakes on T cells without altering their genes, CAR-T physically rewrites the cell's targeting apparatus. It differs from monoclonal antibody therapy, which delivers a manufactured protein rather than living, self-replicating cells; CAR-T cells persist and proliferate inside the body, earning the description "living drug." It is also separate from haematopoietic stem-cell (bone marrow) transplantation, which replaces the blood-forming system rather than redirecting mature immune cells, and from tumour-infiltrating lymphocyte therapy, which expands naturally occurring anti-tumour cells without genetic modification.

The therapy carries serious risks and unresolved controversies. The most common acute toxicity is cytokine release syndrome (CRS), an inflammatory cascade causing high fever, hypotension, and organ stress, managed with the interleukin-6 inhibitor tocilizumab. A related complication, immune effector cell-associated neurotoxicity syndrome (ICANS), can produce confusion, seizures, and cerebral oedema. In November 2023 the FDA opened an investigation into reports of secondary T-cell malignancies arising after CAR-T treatment, and in January 2024 it required a boxed warning on the class. Efficacy against solid tumours remains limited because of antigen heterogeneity and the immunosuppressive tumour microenvironment, and antigen-loss relapse—where cancer cells shed the targeted protein—continues to challenge durability. Cost, manufacturing complexity, and cold-chain logistics restrict access in low- and middle-income settings.

For the working practitioner, particularly those tracking science, technology, and health policy, CAR-T therapy is significant on several fronts. It exemplifies the convergence of genetic engineering and personalised medicine that increasingly features in policy debates over biosecurity, intellectual property, and equitable access. India's NexCAR19 is cited as evidence of indigenous biotechnology capability and is frequently referenced in civil-services examinations under science-and-technology and health themes. The therapy raises governance questions about pricing, insurance coverage, regulatory pathways for living-cell products, and the ethics of gene modification—issues that diplomats and policy officers encounter in global health forums, World Health Organization deliberations, and bilateral technology-transfer negotiations.